JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma.
about
JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indicationsIntegrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemiaSerum levels of interleukin-9 correlate with negative prognostic factors in extranodal NK/T-cell lymphoma.Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type.Molecular basis of targeted therapy in T/NK-cell lymphoma/leukemia: A comprehensive genomic and immunohistochemical analysis of a panel of 33 cell linesDisease-specific mutations in mature lymphoid neoplasms: recent advances.Recent advances in intestinal lymphomas.Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances.Molecular Pathogenesis of Peripheral T Cell Lymphoma.Investigational drugs for T-cell lymphoma.A neutralized human LMP1-IgG inhibits ENKTL growth by suppressing the JAK3/STAT3 signaling pathway.Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cellsEBV-negative aggressive NK-cell leukemia/lymphoma: a clinical and pathological study from a single institution.Development of Selective Covalent Janus Kinase 3 Inhibitors.Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation.JAK/STAT pathway directed therapy of T-cell leukemia/lymphoma: Inspired by functional and structural genomics.The promise of Janus kinase inhibitors in the treatment of hematological malignancies.HiJAKing the epigenome in leukemia and lymphoma.Frequent BCOR aberrations in extranodal NK/T-Cell lymphoma, nasal type.Th17 cytokine differentiation and loss of plasticity after SOCS1 inactivation in a cutaneous T-cell lymphoma.Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma.Coexistence of systemic lupus erythematosus, tuberous sclerosis and aggressive natural killer-cell leukaemia: coincidence or correlated?JAK3-mediated phosphorylation of EZH2: a novel mechanism of non-canonical EZH2 activation and oncogenic functionResveratrol inhibits Extranodal NK/T cell lymphoma through activation of DNA damage response pathwayWhole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma anaplastic large cell lymphoma.Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells.Epstein-Barr virus-negative extranodal "true" natural killer-cell lymphoma harbouring a KDM6A mutation.Advances in the understanding and management of T-cell prolymphocytic leukemia.Recurrent ECSIT mutation encoding V140A triggers hyperinflammation and promotes hemophagocytic syndrome in extranodal NK/T cell lymphoma.Role of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products.Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma.Mutational profiling can identify laryngeal dysplasia at risk of progression to invasive carcinoma.Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target.Activated janus kinase 3 expression not by activating mutations identified in natural killer/T-cell lymphoma.STAT5 inhibition induces TRAIL/DR4 dependent apoptosis in peripheral T-cell lymphoma.Clinical and molecular characteristics of unicentric mediastinal Castleman disease.Aspects moléculaires des lymphomes T périphériques (2)Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma
P2860
Q26782539-746066A9-5D53-4A84-8592-C10B87D4061CQ34106849-F5EF12FE-DE14-43DB-B2B7-1D01940A7774Q35145308-142AB236-1C23-4A5A-B3DA-88155EDD663DQ36232164-F451161C-F52B-417D-BA9A-6E886415C98FQ36372043-D06AB76A-7C66-4852-A283-10B9A07AE815Q38201143-D1E45DAE-5908-4FB9-B67F-B9877744FB0AQ38339462-BE9F0A1A-E3E0-401A-8346-F1FF73879849Q38554422-D8107433-3301-4AE5-9990-2EC868FF9F35Q38597997-5BCD3634-4A72-4143-A782-93FB3C338223Q38635909-B5F309D4-DFD0-4FF4-A520-BB24F99813DAQ38724665-A032F8B4-844D-4C9F-B00A-1B18AB3D84FEQ38741546-9646796B-5106-4A85-9D47-991DF71EDE72Q38761793-34F5A4A0-09E9-4359-AE96-81871E333ACCQ38763094-66CE4B16-275C-44B5-BCE6-564B6F62F34CQ38870624-FB796CBB-57FF-43EF-B2E3-AC68B7C1794AQ39142126-AA6DD430-73D6-4A59-8175-FD014BD7FFF1Q39170500-BF120202-A870-4CEB-A9D4-BDCAC90EEF90Q39237403-019AE901-CDEA-432B-B182-2509804FE0AAQ40101543-EC324CC8-9CEE-4B3A-BE4F-A6AFBDAA80BAQ40688204-29545F38-9FD2-4581-A87E-2D1CF5FE4A5EQ40717160-5876614C-2AD9-4B1F-8E2D-64CAB81B4084Q40766488-B83285E3-133E-4E36-BA5B-DFDDFAC64AF0Q41576148-EA5EF9D1-726E-4086-9BF4-ED2D344F3FCEQ41674995-6AE6ADF2-60FE-44FE-9DD7-714911277265Q42384344-C9CD55B3-DBDF-49A1-853E-D51595A29919Q42827073-DC09ABCD-81A1-4BE1-B6A6-5E6B5FEDCB59Q45328020-0BA8741A-4EAE-4EB4-8511-36D7017645A3Q47113632-D0BFF15A-B44D-412F-B69A-65C14AC32C61Q47240802-0B3B03A4-3C44-4C53-8872-D60389ED3526Q49887894-0128660E-1295-4470-B16D-6CD61CF05039Q50055394-C074A00A-CC52-4AA1-8BA0-3659531349B2Q52560170-B6FA18BA-A35D-419B-BDC5-C08F578456E3Q52718168-C11CB86D-25FD-44E8-8E3D-FC7BD1E49C59Q54342283-F564E0C8-5F9B-4F19-B7AD-0C7AAECA4B3DQ54959839-C9990637-D59C-441B-8A53-8F7657DE74A9Q55360160-A3AF3116-86ED-498C-BBCE-872643DB5955Q57216715-E09CA99A-78A9-418D-BAEC-84766ECC2D46Q58742961-6F15359C-1F16-4D40-B589-A6C68E8CC082
P2860
JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
JAK3 deregulation by activatin ...... natural killer cell lymphoma.
@en
JAK3 deregulation by activatin ...... natural killer cell lymphoma.
@nl
type
label
JAK3 deregulation by activatin ...... natural killer cell lymphoma.
@en
JAK3 deregulation by activatin ...... natural killer cell lymphoma.
@nl
prefLabel
JAK3 deregulation by activatin ...... natural killer cell lymphoma.
@en
JAK3 deregulation by activatin ...... natural killer cell lymphoma.
@nl
P2093
P2860
P50
P356
P1433
P1476
JAK3 deregulation by activatin ...... e natural killer cell lymphoma
@en
P2093
A Aline-Fardin
A Bouchekioua
D Jeziorowska
L Scourzic
O de Wever
P2860
P2888
P304
P356
10.1038/LEU.2013.157
P577
2013-05-21T00:00:00Z